Search - tctmd.com

Displaying 1 - 11 of 11

Sort: Relevancy | Date

Stable CAD Plaque Morphology Improved by PCSK9 Inhibitors: YELLOW III

News Conference News ACC 2023

Stable CAD Plaque Morphology Improved by PCSK9 Inhibitors: YELLOW III

March 04, 2023

Stepwise or Hammer Down? Experts Debate Best Approach to LDL-Lowering

News Conference News EAS 2022

Stepwise or Hammer Down? Experts Debate Best Approach to LDL-Lowering

Michael O'Riordan

May 24, 2022

PACMAN-AMI: Positive Plaque Changes With Early Alirocumab Use in Acute MI

News Conference News ACC 2022

PACMAN-AMI: Positive Plaque Changes With Early Alirocumab Use in Acute MI

April 03, 2022

EVAPORATE Hints at Slowed Plaque Progression With Icosapent Ethyl

News Conference News AHA 2019

EVAPORATE Hints at Slowed Plaque Progression With Icosapent Ethyl

November 18, 2019

Visit-to-Visit BP Variability Linked to Coronary Plaque Progression, Adverse Outcomes

News Daily News

Visit-to-Visit BP Variability Linked to Coronary Plaque Progression, Adverse Outcomes

April 11, 2019

Vulnerable Plaque Components Seen on IVUS Not Linked With MACE, Two New Studies Show

News Daily News

Vulnerable Plaque Components Seen on IVUS Not Linked With MACE, Two New Studies Show

Michael O'Riordan

October 17, 2018

Serial CTA Shines a Light on Statin Effects in Subclinical CAD

News Daily News

Serial CTA Shines a Light on Statin Effects in Subclinical CAD

Yael L. Maxwell

June 15, 2018

News Daily News

Evolocumab Modifies IVUS-Detected Coronary Atherosclerosis: Topline Results From GLAGOV

Michael O'Riordan

September 20, 2016

News Industry News

Amgen Announces Positive Top-Line Results From Phase 3 GLAGOV Imaging Study Of Repatha® (Evolocumab)

September 20, 2016

News Conference News ESC 2013

AQUARIUS: Aliskiren Fails Primary Endpoint But Surprises with MACE Reduction

September 04, 2013

News Conference News ESC 2012

Stem Cells, Nanoparticles Appear to be an Antidote to Atherosclerosis

August 29, 2012

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.